PHERFLOT/IKF-053 Trial at ESMO 2025: Pembrolizumab and Trastuzumab Combined with FLOT in Localized HER2-Positive Esophagogastric Adenocarcinoma
This story is reported by Oncodaily. Read what other outlets are saying below, then open the original report for full details.